| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
STIM1-TFR1-IN-1 (compound S-IN-1) (0.15625-5 μM) can bind directly and specifically to STIM1-CD protein, with a dissociation constant (Kd) of 2.18 μM [1]. In HT22 mouse neurons induced by heme-simulated intracerebral hemorrhage (ICH), S-IN-1 (10-20 μM) inhibited the interaction between STIM1 and TFR1 [1]. In heme-treated HT22 mouse neurons, S-IN-1 (0-40 μM) reduced neuronal ferroptosis and improved neuronal cell viability by decreasing iron accumulation, lipid peroxidation, and reactive oxygen species (ROS) production, while enhancing the antioxidant defense system [1].
|
|---|---|
| ln Vivo |
STIM1-TFR1-IN-1 (compound S-IN-1) (10 mg/kg; orally; once every 24 hours) significantly reduced brain tissue damage and continuously improved sensory, motor and cognitive neurological deficits in a mouse model of cerebral hemorrhage [1].
|
| Animal Protocol |
Animal/Disease Models:C57BL/6J (adult male, 10 weeks old, 20-25 g, induced cerebral hemorrhage by autologous blood injection) [1]
Doses: 10 mg/kg Route of Administration: Oral; once every 24 hours Experimental Results: On day 3 after cerebral hemorrhage, cerebral edema was reduced, the number of surviving neurons increased, and plasma neuron-specific enolase (NSE) levels decreased. On day 3 after cerebral hemorrhage, modified neurological severity score (mNSS), angle test score, cylinder test score, adhesive removal time, and spinner fall latency were significantly improved. Compared with the vehicle control group, within 14 days after ICH, mNSS, angle test score, cylinder test score, adhesive removal time, spinner fall latency, new object position (NOL) discrimination rate, and new object recognition (NOR) discrimination rate were continuously improved. |
| References |
| Molecular Formula |
C15H21N5OS
|
|---|---|
| Molecular Weight |
319.43
|
| CAS # |
2196106-61-1
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C(NC1=NN=C(C2CCC2)N1)[C@@H](N3C=CC=C3)CCSC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1306 mL | 15.6529 mL | 31.3058 mL | |
| 5 mM | 0.6261 mL | 3.1306 mL | 6.2612 mL | |
| 10 mM | 0.3131 mL | 1.5653 mL | 3.1306 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
